Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsShasunpharmaceuticals

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Prefer Aurobindo, Ajanta Pharma, Torrent Pharma: Gujral

      Ashwani Gujral of ashwanigujral.com is of the view that one may prefer Aurobindo Pharma, Ajanta Pharma and Torrent Pharma and likes Glenmark Pharma.

    • Like Strides Arcolab for long term, says Deepak Shenoy

      Deepak Shenoy of Capitalmind.in likes Strides Arcolab for the long term.

    • Like Sun Pharma, Strides Arcolab: Deepak Shenoy

      Deepak Shenoy, Founder of Capitalmind.in likes Sun Pharma and Strides Arcolab and feels that pharma as a space is worth looking into.

    • Buy Lupin, Shasun Pharmaceuticals: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Lupin and Shasun Pharmaceuticals.

    • Buy Shasun Pharma, advises Pritesh Mehta

      According to Pritesh Mehta of IIFL, one can buy Shasun Pharma as the stock may test Rs 370.

    • Top buzzing midcap stocks to trade on June 1

      Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. We have Maruti Suzuki, Eicher Motor, BEML, HCC, Sun Pharma, IL&FS Engg, Hathway Cables, Glenmark Pharma & ITDC.

    • Top buzzing midcap stocks to trade on May 27

      Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. We have Wockhardt, United Spirits, ABG Shipyard, Ballarpur Industries, ITDC & Sun Pharma.

    • Buy Shasun Pharmaceuticals: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one may buy Shasun Pharmaceuticals.

    • See 10% overall growth for Sun-Ranbaxy entity: Surajit Pal

      or the investors who are holding the stock should continue to hold it but fresh entry should be made only if it corrects from the current levels, says Surajit Pal, pharma analyst at Prabhudas Lilladher.

    • Focus on midcap pharma space: Gautam Trivedi

      Gautam Trivedi, MD & CEO of Religare Capital Markets is of the view that one may focus on midcap pharma space.

    • Midcap pharma look attractive: Anand Tandon

      According to Anand Tandon of Market Expert, the midcap pharma sector will continue to look quite attractive.

    • Bull's Eye: Buy Reliance Cap, Ashok Leyland, Shasun Pharma

      Kunal Saraogi, Equityrush advises buying Jain Irrigation for a target price of Rs 83 and Ashok Leyland for a target price of Rs 46.

    • Shasun Pharma may go to Rs 215-220: Ambareesh Baliga

      Market expert, Ambareesh Baliga feels that Shasun Pharmaceuticals may go to Rs 215-220 where one should book out completely.

    • Buy Den Networks, Sadbhav Engg, Shasun Pharma: Kunal Bothra

      Kunal Bothra of LKP recommends buying Den Networks with a target of Rs 169 and suggets buying Arvind.

    • Buy Sun Pharma, Cipla: Gopi Suvanam

      According to Gopi Suvanam, Founder of InvestWorks, one may buy Cipla and Sun Pharmaceutical Industries in the pharma space.

    • Buy Shasun Pharma, M&M, says Pritesh Mehta

      Pritesh Mehta of IIFL advises buying Shasun Pharmaceuticals with a target of Rs 81 and Mahindra and Mahindra (M&M) with a target of Rs 950.

    • Super Six: Top chart picks for November 1

      Pritesh Mehta of IIFL suggests buying Shasun Pharmaceuticals with a target of Rs 80 and Cairn India with a target of Rs 340.

    • Do not buy Tata Steel, prefer Idea Cellular: SP Tulsian

      According SP Tulsian of sptulsian.com, one should not buy Tata Steel. "One may prefer Idea Cellular, which has corrected today," he adds.

    • Exit Shasun Pharmaceuticals, says Parag Doctor

      Parag Doctor, Head - Trading Strategies at Keynote Capital's is of the view that one may exit Shasun Pharmaceuticals in current rally.

    • Shasun Pharma may move to Rs 92: Thununguntla

      Jagannadham Thununguntla, Strategist & Head of Research, SMC Global Securities Limited feels Shasun Pharmaceuticals can move to Rs 92.

    • Buy Dewan Housing, Shasun Pharma, Kalpataru Power: Lancelot

      Lancelot D Cunha of Sharyans Wealth Management recommends to buy Dewan Housing Finance Corporation with a target price of Rs 164.10 and Shasun Pharma with a target price of Rs 55.80.

    • Bull's Eye: Buy UCO Bank, Indiabulls Real, Kalpataru Power

      Aashish Tater of Fortunewizard.com advises buying Siti with a target price of Rs 22 and Dena Bank with a target price of Rs 74.

    • Prefer Dr Reddy, Cipla over Shasun Pharma: Sukhani

      Sudarshan Sukhani, s2analytics.com advises to switch from Shasun Pharmaceuticals to Dr Reddy and Cipla.

    • Avoid Dishman Pharma, says SP Tulsian

      SP Tulsian, sptulsian.com don‘t think that Dishman Pharma can correct below Rs 84-85. He feels the major correction seems to have got factored in. However, he still feels one should not invest in Dishman Pharma even at current levels.

    • Sell IVRCL, HDIL, IFCI: Pankaj Jain

      In CNBC-TV18's popular show Bull's Eye, Pankaj Jain of Sunteck Wealthmax shares trading strategy of the day.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347